Hyperlipoproteinemia Type III
Showing 1 - 25 of >10,000
Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1, Hypercholesterolemia, Familial, 2 Trial in Moscow (genetic,
Recruiting
- Hypercholesterolemia, Familial
- +25 more
- Genetic Testing
- +7 more
-
Moscow, Russian FederationNational Medical Research Centre for Therapy and Preventive Medi
Jul 25, 2022
Familial Hypercholesterolemia, Familial Hypercholesterolemia Due to Genetic Defect of Apolipoprotein B, Familial
Recruiting
- Familial Hypercholesterolemia
- +7 more
- Research-based genetic test for Familial Hypercholesterolemia
-
Vancouver, British Columbia, Canada
- +1 more
Jan 31, 2022
Primary Hypercholesterolemia, Mixed Hyperlipemia Trial in Guangzhou (SHR-1209, SHR-1209 Placebo)
Active, not recruiting
- Primary Hypercholesterolemia
- Mixed Hyperlipemia
- SHR-1209
- SHR-1209 Placebo
-
Guangzhou, Guangzhou, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Jun 9, 2022
Heterozygous Familial Hypercholesterolemia Trial in Beijing (Ongericimab, Placebo)
Recruiting
- Heterozygous Familial Hypercholesterolemia
- Ongericimab
- Placebo
-
Beijing, Beijing, ChinaBeijing Anzhen Hospital Capital Medical University City:Beijing
Apr 12, 2022
The Spanish Familial Hypercholesterolaemia Cohort Study
Recruiting
- Familial Hypercholesterolaemia
-
Madrid, SpainFundacion Hipercolesterolemia Familiar
Nov 8, 2021
Hypercholesterolemia, Familial Hypercholesterolemia Trial (Ezetimibe, Rosuvastatin)
Completed
- Hypercholesterolemia
- Familial Hypercholesterolemia
- (no location specified)
Feb 7, 2022
Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia Trial (EZ 10 mg/Atorva 20 mg FDC, EZ 10 mg/Atorva 10 mg FDC)
Completed
- Hypercholesterolemia
- Heterozygous Familial Hypercholesterolemia
- EZ 10 mg/Atorva 20 mg FDC
- EZ 10 mg/Atorva 10 mg FDC
- (no location specified)
Feb 7, 2022
Efficacy and Safety, Heterozygous Familial Hypercholesterolemia, PCSK9 Trial in Shenzhen (protein convertase subtilisin/kexin
Active, not recruiting
- Efficacy and Safety
- +2 more
- protein convertase subtilisin/kexin type 9 inhibitor
-
Shenzhen, Guangdong, Chinaxili People's Hospital
Aug 24, 2021
Familial Hypercholesterolemia - Homozygous, Lipid Metabolism Disorders, Proprotein Convertase Subtilisin/Kexin 9 Trial in
Recruiting
- Familial Hypercholesterolemia - Homozygous
- +2 more
- IBI306
-
Shenzhen, Guangdong, Chinaxili People's Hospital
Jun 29, 2021
Hyperlipoproteinemia Type I, Hypertriglyceridemia Trial in Dallas (Orlistat)
Active, not recruiting
- Hyperlipoproteinemia Type I
- Hypertriglyceridemia
-
Dallas, TexasUT Southwestern Medical Center 5323 Harry Hines Blvd
Jan 23, 2022
Homozygous Familial Hypercholesterolaemia (HoFH) Trial in Worldwide (Lomitapide)
Recruiting
- Homozygous Familial Hypercholesterolaemia (HoFH)
-
Heidelberg, Baden-Wurttemberg, Germany
- +13 more
Apr 4, 2022
Cesarean Section, Quadratus Lumborum Block, Transversus Abdominis Plane Block Trial in Cairo (Quadratus lumborum block typen II,
Completed
- Cesarean Section
- +2 more
- Quadratus lumborum block typen II
- +2 more
-
Cairo, EgyptThe General Authority for Teaching Hospitals and Institutes
Jul 22, 2023
Familial Hypertriglyceridemia Trial (Heredity for cardiovascular disease, Heredity for pancreatitis, Heredity for type 2
Active, not recruiting
- Familial Hypertriglyceridemia
- Heredity for cardiovascular disease
- +3 more
- (no location specified)
Oct 23, 2023
Familial Hyperlipidemia Trial
Not yet recruiting
- Familial Hyperlipidemia
- (no location specified)
Apr 12, 2023
LDL Hyperlipoproteinemia, Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia, Triglyceride Storage Type I or II Disease
Not yet recruiting
- LDL Hyperlipoproteinemia
- +2 more
- omega-3 fatty acids
- Placebo
-
Novosibirsk, Novosibisk Region, Russian FederationCenter of New Medical Technologies
Nov 30, 2023
Type 1 Hyperlipoproteinemia Trial in Dallas (SLx-4090 , Orlistat Placebo, Orlistat)
Terminated
- Type 1 Hyperlipoproteinemia
- SLx-4090 placebo
- +3 more
-
Dallas, Texas
- +1 more
Jul 26, 2021
Familial Hypercholesterolemia Trial
Not yet recruiting
- Familial Hypercholesterolemia
- (no location specified)
Apr 11, 2023
Advanced Lipoproptein Profiling and Cardiovascular Risk
Recruiting
- Familial Hypercholesterolemia
- Atherosclerosis
- Additionnal blood samples
-
Paris, FranceHôpital de la Pitié Salpêtrière
Aug 2, 2022
Familial Hypercholesterolemia Trial in Philadelphia (Cascade screening)
Enrolling by invitation
- Familial Hypercholesterolemia
- Cascade screening
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania, Perelman School of Medicine
Feb 27, 2023
Dental Implant Trial (Type I Dental implant placement., Type II Dental implant placement., Type III/IV dental implant
Not yet recruiting
- Dental Implant
- Type I Dental implant placement.
- +2 more
- (no location specified)
Aug 4, 2023
Obesity, Morbid Trial (metabolic surgery (SADIS and OAGB))
Not yet recruiting
- Obesity, Morbid
- metabolic surgery (SADIS and OAGB)
- (no location specified)
Jul 10, 2023
Hypoglycemia in Glycogen Storage Disease Type III
Recruiting
- Glycogen Storage Disease Type III
- No Intervention
-
Philadelphia, Pennsylvania
- +1 more
Jul 22, 2022
Hypercholesterolemia, Familial Hypercholesterolemia Trial (MK-0616, Placebo)
Not yet recruiting
- Hypercholesterolemia
- Familial Hypercholesterolemia
- MK-0616
- Placebo
- (no location specified)
Jul 10, 2023
Homozygous Familial Hypercholesterolemia Trial (SHR-1918)
Not yet recruiting
- Homozygous Familial Hypercholesterolemia
- (no location specified)
Aug 22, 2023